Number of the records: 1  

Molecular differences of adipose-derived mesenchymal stem cells between non-responders and responders in treatment of transphincteric perianal fistulas

  1. 1.
    SYSNO ASEP0549766
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleMolecular differences of adipose-derived mesenchymal stem cells between non-responders and responders in treatment of transphincteric perianal fistulas
    Author(s) Tencerová, Michaela (FGU-C) RID, ORCID
    Lundby, L. (DK)
    Buntzen, S. (DK)
    Norderval, S. (NO)
    Hougaard, H. T. (DK)
    Pedersen, B. G. (DK)
    Kassem, M. (DK)
    Article number586
    Source TitleStem Cell Research & Therapy. - : BioMed Central
    Roč. 12, č. 1 (2021)
    Number of pages12 s.
    Languageeng - English
    CountryGB - United Kingdom
    Keywordsautologous adipose tissue graft injection ; transsphincteric perianal fistula ; adipose-derived mesenchymal stem cells ; stem cell potency ; fistula healing
    Subject RIVEA - Cell Biology
    OECD categoryCell biology
    Method of publishingOpen access
    Institutional supportFGU-C - RVO:67985823
    UT WOS000722212900002
    EID SCOPUS85119874897
    DOI10.1186/s13287-021-02644-8
    AnnotationBackground: Injection of autologous adipose tissue (AT) has recently been demonstrated to be an effective and safe treatment for anal fistulas. AT mesenchymal stem cells (AT-MSCs) mediate the healing process, but the relationship between molecular characteristics of AT-MSCs of the injected AT and fistula healing has not been adequately studied. Thus we aimed to characterize the molecular and functional properties of AT-MSCs isolated from autologous AT injected as a treatment of cryptogenic high transsphincteric perianal fistulas and correlate these findings to the healing process.Methods: 27 patients (age 45 +/- 2 years) diagnosed with perianal fistula were enrolled in the study and treated with autologous AT injected around the anal fistula tract. AT-MSCs were isolated for cellular and molecular analyses. The fistula healing was evaluated by MRI scanning after 6 months of treatment. AT-MSC phenotype was compared between responders and non-responders with respect to fistula healing.Results: 52% of all patients exhibited clinical healing of the fistulas as evaluated 6 months after last injection. Cultured AT-MSCs in the responder group had a lower short-term proliferation rate and higher osteoblast differentiation potential compared to non-responder AT-MSCs. On the other hand, adipocyte differentiation potential of AT-MSCs was higher in non-responder group. Interestingly, AT-MSCs of responders exhibited lower expression of inflammatory and senescence associated genes such as IL1B, NFKB, CDKN2A, TPB3,TGFB1.Conclusion: Our data suggest that cellular quality of the injected AT-MSCs including cell proliferation, differentiation capacity and secretion of proinflammatory molecules may provide a possible mechanism underlying fistula healing. Furthermore, these biomarkers may be useful to predict a positive fistula healing outcome.
    WorkplaceInstitute of Physiology
    ContactLucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400
    Year of Publishing2022
    Electronic addresshttps://doi.org/10.1186/s13287-021-02644-8
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.